Ann: Midkine Symposium Munich, page-7

Nice to hear from you Leverage, hope your well mate. Yes its a tough one. I thought it was a fantastic update.

I've come to the conclusion that both the breadth and depth of Midkine as a target actually puts people off. Its the disbelief factor. Its too hard to process that a company this size could possibly detect all types of cancer, and have a role in curing heart disease, kidney disease, inflammation, cancer etc.

Plus of course the ten years so far sad face stories don't help new investors. In a way i also think right now if CDY did not have mid kine it would already be valued higher as just the consumer health story would be easier to understand on its own.


Either way time will tell. Ill be on the buy side in the morning.